116 results about "Atherosclerotic disease" patented technology

A laser catheter is disclosed wherein optical fibers carrying laser light are mounted in a catheter for insertion into an artery to provide controlled delivery of a laser beam for percutaneous intravascular laser treatment of atherosclerotic disease. A transparent protective shield is provided at the distal end of the catheter for mechanically diplacing intravascular blood and protecting the fibers from the intravascular contents, as well as protecting the patient in the event of failure of the fiber optics. Multiple optical fibers allow the selection of tissue that is to be removed. A computer controlled system automatically aligns fibers with the laser and controls exposure time. Spectroscopic diagnostics determine what tissue is to be removed.

Techniques and devices for treating atherosclerotic disease use controlled cryogenic cooling, often in combination with angioplasty and / or stenting. A combination cryogenic / angioplasty catheter may cool the diseased blood vessel before, during, and / or after dilation. Controlled cooling of the vessel wall reduces actual / observed hyperplasia as compared to conventional uncooled angioplasty. Similar reductions in restenosis may be provided for other primary treatments of the blood vessel, including directional arthrectomy, rotational arthrectomy, laser angioplasty, stenting, and the like. Cooling of vessel wall tissues will often be performed through plaque, and the cooling process will preferably take the thermodynamic effects of the plaque into account.

Devices for excluding aneurysms and treating atherosclerotic disease, for intra-aneurysmal occlusion; and devices for preventing distal emboli. The devices are generally pliable and collapsible thin film devices which can be delivered via a microcatheter into the desired location where they are deployed and undergo either a shape memory phase transformation or in situ polymerization to assume the stable configuration of a permanent endoluminal prosthesis. Prior to being caused to assume their final shape, the devices remain soft, collapsible and pliable to ensure atraumatic delivery through the vascular system. Upon reaching the endoluminal defect in the vessel, the device is extruded from the microcatheter. Devices are also provided for retrieving clots.

Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.

The invention provides a novel human Mab Fab, cloned by phage display, and its use in diagnostic and therapeutic methods. In particular the invention provides a method for analyzing the OxLDL components of atherosclerotic plaques in vivo and a means to determine their relative pathology. As the method is based on a human Fab rather than a mouse Mab, the progress or regression of the disease may be monitored over time. The antibody may also be used for the analysis of surgical or serum samples ex vivo for the presence of OxLDL. The antibody may also be used to target therapeutic agents to the site of atherosclerotic plaques or may have use as a therapeutic agent itself.

The present invention relates to compounds of the formula (I) wherein R1, R2, R3, R4, R5, X1, X2, X3, X4, n, and k are defined in the description and claims, and pharmaceutically acceptable salts and / or pharmaceutically acceptable esters thereof. The compounds are useful for in the treatment and prophylaxis of diseases which are modulated by LXRα and / or LXRβ agonists, including increased lipid and cholesterol levels, particularly low HDL-cholesterol, high LDL-cholesterol, atherosclerotic diseases, diabetes, particularly non-insulin dependent diabetes mellitus, metabolic syndrome, dyslipidemia, Alzheimer's disease, sepsis, inflammatory diseases such as colitis, pancreatitis, cholestasis / fibrosis of the liver, and diseases that have an inflammatory component such as Alzheimer's disease or impaired / improvable cognitive function.

Techniques and devices for treating atherosclerotic disease use controlled cryogenic cooling, often in combination with angioplasty and / or stenting. A combination cryogenic / angioplasty catheter may cool the diseased blood vessel before, during, and / or after dilation. Controlled cooling of the vessel wall reduces actual / observed hyperplasia as compared to conventional uncooled angioplasty. Similar reductions in restenosis may be provided for other primary treatments of the blood vessel, including directional arthrectomy, rotational arthrectomy, laser angioplasty, stenting, and the like. Cooling of vessel wall tissues will often be performed through plaque, and the cooling process will preferably take the thermodynamic effects of the plaque into account.

This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.

This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.

The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.

This invention provides cholesterol absorption inhibitors of Formula I:and the pharmaceutically acceptable salts thereof, wherein R12 is an alkyl, alkeny or alkynyl group mono- or poly-substituted with —OH, —COOH or a combination of—OH and —COOH, and R9 contains an alkyl, alkeny or alkynyl group substituted with a heterocyclic ring, amino or sulfonyl. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating atherosclerosis and preventing atherosclerotic disease events.

The present invention uses several innovative means in order to place two stents into branched arteries that have atherosclerotic disease. The stent delivery catheter has means to place two separate guide wires into the two arteries, deploy the first stent in the main artery and provide an opening in the stent as well as a guide wire in the branch artery for the second stent carrying catheter to be threaded into the branch artery.

This invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment also are described.

The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder by obtaining a level of the marker of systemic inflammation in the individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorder.

5-cholesten, 3β, 25-diol, disulfate (25HCDS) has been found to be an authentic PPARγ agonist and LXR antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.

Methods of utilizing a combined administration or a unit dosage of a combination of an HMG-CoA inhibitor and omega-3 fatty acids for the reduction of apolipoprotein-B levels. The methods are especially useful in the treatment of patients with hypertriglyceridemia or hypercholesterolemia or mixed dyslipidemia, coronary heart disease (CHD), vascular disease, atherosclerotic disease and related conditions, and for the prevention or reduction of cardiovascular, cardiac, and vascular events.

The present invention provides a compound of formula (I) having an excellent JAK3 inhibition activity and being useful as an active ingredient of an agent for treating and / or preventing various immune diseases including autoimmune diseases inflammatory diseases, and allergic diseases. The compound according to the present invention has an inhibition activity against JAK3 and is thus useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transmission (e.g., rejection during organ / tissue transplantation, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, Alzheimer's disease, and atherosclerotic disease), or diseases caused by abnormal cytokine signal transmission (e.g., cancer and leukemia).

Dietary supplements useful for treating or preventing cardiac disease are disclosed According to some embodiments, the presently disclosed supplement includes a pomegranate product fermented with a statin-producing fungus such one or more of Monascus, Aspergillus, Penicillium, Pleurotus, Pythium, Hypomyces, Paelicilomyces, Eupenicillium, and Doratomyces. Alternatively or additionally, the presently disclosed supplement includes a pomegranate product in combination with a plant product, such as a grain product and a legume, fermented with the statin-producing fungus. Optionally, the supplement includes at least one of coenzymeQ10 and a tocopherol. The presently disclosed dietary supplements include both a COX-2 inhibitor and a HMG-CoA reductase inhibitor, and in some embodiments, the supplement is useful for reducing or controlling blood cholesterol for managing atherosclerotic disease, and / or for managing blood pressure. Methods of preparing the presently disclosed dietary supplement are also provided.

The invention discloses a solid lipid nanoparticle containing andrographolide, a preparation method and application thereof. The solid lipid nanoparticle is composed of 1-20% andrographolide, 20-60% lipid material and 30-60% emulsifier. The preparation of described solid lipid nanoparticle comprises: adding andrographolide, lipid material and emulsifier in the organic solvent, heating makes to dissolve completely; The organic solvent is evaporated, is cooled with ice bath to form solid; Take Tween- Dissolve 80 in water to obtain the water phase; mix the obtained solid with the obtained water phase, and stir at high speed to disperse the solid uniformly to obtain colostrum; perform high-pressure homogenization treatment at room temperature, and then rapidly cool on an ice bath. The solid lipid nanoparticles containing andrographolide can be used in the form of a single form or a combination with a pharmaceutically acceptable drug carrier for the prevention and treatment of hyperlipidemia and / or atherosclerosis In the preparation of pharmaceutical preparations.

Methods, devices, and kits, for assessing luminal lesions rely on intraluminal detection of labeled annexin. Annexin coupled to a detectable marker is introduced to a body lumen, either into the lumen itself or systemically in patient circulation, and localizes at a lesion. The detector is introduced into the body lumen and the localize distribution of the detectable marker is detected in situ. The information is useful for a number of purposes including the identification of unstable plaque in patients suffering from atherosclerotic disease.

The invention discloses a serum or RLP density in the plasma testing method, which is characterized by the following: adopting immune combined direct method or immune sediment separating method; providing effective estimation and reference accordance for atherosclerotic disease, coronary disease and relative metabolic disease of atherosclerotic disease.

The invention discloses an SAA (serum amyloid A) immunochromatographic test strip and a preparation method and a test method thereof. The test strip comprises a sample pad, a combination pad, an analyzing membrane, a water-absorbing pad, a bottom board, a testing tape T line and a quality control tape C line, wherein the analyzing membrane is adhered on the upper portion of the bottom board, the combination pad and the water-absorbing pad are adhered at two ends of the upper portion of the analyzing membrane respectively, the sample pad is adhered at one end of the upper portion of the combination pad, and the testing tape T line and the quality control tape C line are adhered on the analyzing membrane. The SAA immunochromatographic test strip and the preparation method and the test method thereof have the advantages that anti-SAA antibody protein is used for achieving rapid testing of high sensitivity and high specificity of SAA antibodies in a sample by indirect immunoassay, so that bases for auxiliary diagnosis of diseases such as infectious diseases, tissue damage necrotic diseases, atherosclerotic diseases, immune diseases and rejection after organ transplantation are provided.

The instant invention provides novel cholesterol absorption inhibitors of Formula I and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.

The invention relates to a device for culturing endothelial cells of myocardial bridge-mural coronary artery, which is characterized in that a pair of myocardial bridge press block and simulated coronary artery is arranged in an airtight cavity, a motor drives the myocardial bridge press block to press the simulated coronary artery, and the outer part of the airtight cavity is connected with a proportional pressure-regulating constant-current stabilizer consisting of an air compressor, an air reservoir, a proportional pressure valve and a tank pressure sensor; after a periodic pulsatile flow produced by a heart pump passes through an energy accumulator, the liquid is divided into two branches, i.e. one branch of the fluid flows through a division to flow into a liquid storage tank and a constant temperature device after loading, and the other branch of the fluid flows through the airtight cavity to flow into the liquid storage tank and the constant temperature device after loading. Inthe invention, the endothelial cells are cultured in the pulsatile flow, so that the physiological environment of the coronary artery periodically oppressed by the myocardial bridge can be simulated,and the stress on the endothelial cells in the coronary artery can be independently adjusted relatively, therefore, the method of the invention provides an experimental means for studying the relation between the form and function of the endothelial cell and the proximal coronary atherosclerotic diseases in the presence of the myocardial bridge.

The invention provides drugs used for treating atherosclerotic diseases such as carotid artery stenosis, lower extremity atherosclerotic occlusive disease, and coronary heart disease, and more specifically discloses applications of compound Szeto-Schiller-31 (SS-31) in preparing drugs or preparations used for treating atherosclerosis and related diseases, and belongs to the field of medicine, and more specifically belongs to the field of novel pharmaceutical applications of compounds. It is found via experiments that SS-31 is capable of reducing atherosclerosis degree, reducing mouse arterial ROS level obviously, reducing oxidative damage, increasing ATP level, reducing the content of macrophages at atherosclerotic plaques obviously, increasing the content of smooth muscle cells and the content of collagen at atherosclerotic plaques obviously, stabilizing atherosclerotic plaques, improving inflammation level obviously, and reducing expression of lipid intake protein at atherosclerotic plaques; and it is shown by results that SS-31 is capable of treating atherosclerosis and related diseases.

This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in preparation of indane acetic derivatives and to methods of preparation.

Polynucleotide sequences are provided that correspond to genes that are differentially expressed in atherosclerotic disease conditions. Methods for using these sequences to detect gene expression and / or for transcriptional profiling in mammals are also provided. The polynucleotide sequences of the invention may be used, for example, to diagnose atherosclerotic disease, to monitor extent of progression or efficacy of treatment or to assess prognosis of atherosclerotic disease, and / or to identify compounds effective to treat an atherosclerotic disease condition.

The invention provides a traditional Chinese medicine composition for treating a lower extremity atherosclerotic disease (LEAD). The traditional Chinese medicine composition comprises 25-40 parts of radix astragali and 10-20 parts of mulberry, also can comprise 10-20 parts of radix salviae miltiorrhizae, 10-20 parts of Chinese angelica, 6-12 parts of earthworm and 5-8 parts of leech, and can further comprise 6-12 parts of rhizoma acori tatarinowii, 6-12 parts of rhizoma alismatis, 5-15 parts of tea tree root and 5-18 parts of radix achyranthis bidentatae in parts by weight. The invention also provides application of the traditional Chinese medicine composition in preparing a medicine for treating the LEAD. The traditional Chinese medicine composition provided by the invention has the advantages that the medicine offers syndrome differentiation and treatment with the characteristics of traditional Chinese medicine according to the symptoms of the LEAD, and has the effects of activating blood, dredging collaterals and resolving phlegm while placing extra emphasis on replenishing qi and tonifying deficiency so as to fundamentally improve the constitution of a patient, cut the links of worsening the phlegm, deficiency and stasis under a mutual effect, reduce the danger of transferring vessel impediment to heart in terms of prevention and control and realize an obvious curative effect; and the composition does not have toxic and side effects, is easily accepted by the patient, is made from few raw materials, is low in cost, and adopts a simple preparation technology.